{"brief_title": "CPG 7909 Injection in Melanoma", "brief_summary": "To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.", "condition": "Carcinoma, Melanoma", "intervention_type": "Drug", "intervention_name": "CPG 7909 Injection", "description": "CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.", "arm_group_label": "CPG 7909 Injection 40 mg", "other_name": "ProMune, PF-03512676", "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed melanoma that is metastatic. - Measurable disease according to the RECIST criteria. - Karnofsky Performance Status of > 70. Exclusion Criteria: - Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant chemotherapy other than DTIC). - Suspected or known CNS metastases.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00070642.xml"}